

1 **Title**

2

3 Large-scale blood mitochondrial genome-wide study provides novel insights into mitochondrial
4 disease-related traits

5

6 **Authors**

7

8 Cannon S^{1*}, Hall T^{1*}, Hawkes G^{1*}, Colclough K², Boggan RM³, Wright CF¹, Pickett SJ³, Hattersley AT¹,
9 Weedon MN¹, Patel KA¹

10 **Affiliations**

11 ¹ Department of Clinical and Biomedical Sciences, University of Exeter Medical School, RILD building,
12 Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK

13 ² Exeter Genomics Laboratory, Royal Devon University Healthcare, RILD

14 ³ Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute,
15 Newcastle University

16

17 *Equal contribution

18

19 **Corresponding authors**

20 Dr Kashyap A Patel

21 Department of Clinical and Biomedical Sciences, University of Exeter Medical School, RILD building,
22 Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK

23

24 Email : K.A.Patel@exeter.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Abstract**

26

27 **Background/Objectives:** Whole genome sequencing (WGS) from large cohorts enables the study of
28 mitochondrial DNA (mtDNA) variation on human health. We aimed to investigate the influence of
29 common, rare, and pathogenic mtDNA variants on 15 mitochondrial disease-related phenotypes.

30

31 **Methods:** Using WGS from 179,862 individuals from in the UK Biobank, we identified mtDNA
32 variants using MitoHPC. We performed extensive association analyses with 15 mitochondrial
33 disease-relevant phenotypes. We compared the results for the m.3243A>G variant with those from a
34 clinically referred patient cohort.

35

36 **Results:** Of 15,881 mtDNA variants, 12 homoplasmic and one heteroplasmic variant had genome-
37 wide significant associations. All homoplasmic variants increased aspartate aminotransferase level
38 and three were novel, low frequency, variants (MAF~0.002 and beta~0.3 SD). Only m.3243A>G
39 (MAF=0.0002) associated with diabetes (OR=5.6, 95%CI [3.2-9.9]), deafness (OR=12.3, 95%CI [6.2-
40 24.4]) and heart failure (OR=39.5, 95%CI [9.76-160.1]). Multi-system disease risk and penetrance of
41 all three traits increased with m.3243A>G level. Diabetes risk was further influenced by common
42 nuclear genome variation. The penetrance of diabetes with m.3243A>G in the UK Biobank was lower
43 than clinically referred patients, partly attributed to lower heteroplasmy. Of 73 pathogenic
44 mitochondrial disease variants, most were rare in the population with low penetrance.

45

46 **Conclusion:** Our study highlights the utility of WGS for investigating mitochondrial genetics within a
47 large, unselected population. We identified novel associations and demonstrated that pathogenic
48 mitochondrial variants have lower penetrance in clinically unselected than clinically referred
49 settings. m.3243A>G associated with mitochondrial-related phenotypes at higher heteroplasmy. Our
50 findings suggest potential benefits of reporting incidentally identified m.3243A>G at high
51 heteroplasmy levels.

52

53 Introduction

54 Mitochondrial function is fundamental to human life but can be impaired by pathogenic
55 mitochondrial (mt)DNA variants, leading to disease with variable expressivity and penetrance (1, 2,
56 3). Studies of predominantly clinically ascertained cohorts have identified >90 pathogenic variants in
57 the mitochondrial genome (1, 2, 4, 5). These variants cause rare heterogeneous mitochondrial
58 disorders, including complex multi-organ disease (1). Multiple studies have also reported mtDNA
59 variants associated with complex diseases such as maternally-inherited diabetes (6), metabolic
60 diseases (7, 8), Parkinson disease (9), neuroticism (10), as well as stroke and psoriasis (11), among
61 others. These variants provide insight into the function of human mitochondria and the
62 pathogenesis underlying these diseases (12).

63 Previous mitochondrial DNA studies have had limitations. For example, when identifying
64 mitochondrial variants which affect complex traits, studies have either assessed a subset of common
65 variants ($n \sim 700$) in large, unselected cohorts (13, 14), or all variants in small, often clinically selected
66 cohorts ($n=100-2800$) focussing on a certain phenotype (15, 16). Studies of pathogenic variants have
67 been primarily restricted to patients and family members with certain phenotypes, likely resulting in
68 over-inflated penetrance and expressivity estimates as seen for nuclear pathogenic variants (17, 18,
69 19). Large-scale rare and common mitochondrial genome-wide association studies in clinically
70 unselected populations can overcome these limitations, and lead to novel insights into the impact of
71 mitochondrial variants on human health (20).

72 The recent availability of whole genome sequencing data (WGS) from large cohorts provides a
73 unique opportunity to study rare and common mitochondrial variants. WGS data have recently been
74 made available in large population cohorts such as the UK Biobank (UKB, $n=200,030$) (21) and All of
75 Us (22). WGS captures information from both mitochondrial DNA (mtDNA) and nuclear DNA,
76 providing high-quality genotyping for all mitochondrial variations, both rare and common.
77 Importantly, it also provides accurate data on variant heteroplasmy (proportion of mtDNA molecules
78 with alternate allele) and mtDNA copy number (mtCN), making it an ideal technology to study all,
79 and particularly rare, heteroplasmic and homoplasmic mitochondrial variation (23). These large
80 cohort studies also provide excellent opportunity to assess penetrance and expressivity of known
81 pathogenic variants in a clinically unselected population which is crucial before considering the
82 incidental reporting of mitochondrial variants.

83 Here we use WGS data from a large multi-ethnic population cohort of 200,030 individuals from the
84 UKB. We aimed to identify novel rare and common variants associated with 15 common
85 mitochondrial disease-related traits and assess the prevalence and penetrance of known pathogenic
86 variants in an unselected population cohort.

87 **Methods**

88 **Study subjects**

89 *UK biobank*

90 The UKB is an ethically-approved population cohort of ~500,000 individuals from the UK (24). The
91 UKB contains deep phenotype data from self-reporting, hospital and GP records, and measurements
92 of 30 blood biomarkers including HbA1c and liver enzymes, which are paired with detailed genetic
93 data. Whole exome sequencing and genotyping array imputation data are available in the entire
94 cohort, and at the time of writing (May 2023). WGS data is available on 200,030 participants of
95 diverse genetic ancestries. The lack of selection on any specific disease phenotypes, and large
96 sample size, makes it an ideal cohort to study rare genotype-phenotype associations. Cohort
97 characteristics of individuals included in the current study are summarised in Table S1.

98

99 *Clinically identified probands with m.3243A>G pathogenic variant*

100 We included 95 probands who were referred from routine diabetes clinics in the UK to Exeter
101 Genomics laboratory, Royal Devon University Healthcare Hospital with suspected mitochondrial-
102 related diabetes and found to harbour the m.3243A>G variant. The study was approved by the
103 Wales Research ethics Committee 5 (22/WA/0268). Cohort characteristics for these individuals are
104 summarised in Table S2.

105

106 *Clinical phenotypes*

107 We analysed 15 diseases/traits that have been commonly associated with mitochondrial disease (1)
108 (25) and were possible to generate from the data available in the UKB. We used self-report data,
109 ICD9/10 codes, medication, and biomarkers to find these phenotypes (Table S3).

110

111 **Genetic data**

112 *Whole genome sequencing data*

113 UKB generated WGS alignment files (CRAM format) using the deCODE pipeline as previously
114 described (21). Briefly, 500ng of genomic DNA per-sample underwent paired-end sequencing of 150
115 base pairs on Illumina NovaSeq6000 sequencers with the S4 flow cell and real time base calling. Data

116 were aligned to GRCh38 before undergoing contamination and data quality control. A detailed
117 description is available from webpage
118 <https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=180>. We derived genetic ancestry for
119 Europeans (EUR-like), Africans (AFR-like) and South Asians (SAS-like) via comparison of genotypes
120 derived from the UK Biobank Axiom Array to nuclear genome principal components derived from the
121 1000 genomes project.

122

123 *Mitochondrial variant calling from whole genome sequencing data*

124 We used MitoHPC with Mutect2 in mitochondrial mode to acquire mitochondrial variants from the
125 WGS CRAM files of the 200,030 participants (26) (27). MitoHPC is specifically designed to detect
126 mitochondrial single nucleotide variants (SNV) in large WGS datasets and provides accurate
127 heteroplasmy estimates by using a consensus mitochondrial sequence for each sample. MitoHPC
128 also provides mitochondrial copy number estimation (as a proportion of reads mapped to the
129 mitochondrial and nuclear genomes), haplogroup determination, sequencing coverage statistics, as
130 well as quality metrics at both sample and variant levels.

131

132 We used stringent sample exclusion criteria to minimise false-positive low heteroplasmic variant
133 calls. We excluded potentially contaminated samples (e.g. multiple dominant haplogroups in a single
134 sample n=736), samples with low coverage (min <200x or mean <500x, n=1126), or samples with
135 multiple nuclear DNA of mitochondrial origin (nuMT) variants flagged by MitoHPC (n=17,485) (26).
136 Extremes of mitochondrial copy number (Q1-1.5xIQR and Q3+1.5xIQR, n=13), were also excluded.
137 An additional 821 samples were excluded where low quality, or missing, genotype data excluded
138 them from the generation of a genetic relatedness matrix (n=731) or were not able to be processed
139 by MitoHPC (n=90). In total, Of the 199,209 samples that were processed by MitoHPC, 179,862
140 (90.3%) samples passed our robust sample filtering.

141

142 Our variant level filtering was in line with previous large studies (20). Specifically, we removed low
143 quality variants identified by GATK FilterMutectCalls as well as multiallelic indels and those identified
144 within six known low complexity regions (20) or at 382 nuMT sites determined by MitoHPC (26). This
145 provided us with 15,881 variants in 179,862 individuals. Of these, 12,009 (~76%) variants had a
146 minor allele frequency <0.01% which would not have been reliably captured using genotyping array
147 technology (28) and 8,896 variants (56%) had minor allele count (MAC) ≥ 5 . Given our stringent
148 filtering criteria, our primary analysis used variants with $\geq 3\%$ heteroplasmy. We also performed

149 sensitivity analysis for variants with $\geq 5\%$ and $\geq 10\%$ heteroplasmy, as shown in Table 1, to remove
150 the possible false association by low level mitochondrial heteroplasmic calls.

151

Definition	Reference genotype	Heteroplasmic	Homoplasmic
Primary	<3	≥ 3 and <97	≥ 97
Sensitivity	<5	≥ 5 and <95	≥ 95
Sensitivity	<10	≥ 10 and <90	≥ 90

152 **Table 1 – Heteroplasmy (%) thresholds used to define heteroplasmic and homoplasmic variants.**

153

154 *Type 2 Diabetes (T2D) genetic risk score*

155 We generated a T2D genetic risk score for individuals in the UKB based on 88 T2D associated
156 variants from genotyping array as identified in previous genome wide association studies (29) (30)
157 that did not include the UKB. We also generated the partitioned T2D scores as described by Udler *et*
158 *al.* (2018)(31).

159

160 *m.3243A>G testing for clinically referred probands*

161 We used digital droplet PCR (ddPCR) on a Bio-Rad (California, USA) machine to analyse blood DNA for
162 presence of and to determine heteroplasmy of m.3243A>G. PCR primer sequences for the m.3243A>G
163 ddPCR assay are described by Singh *et al* (2006)(32). Plates were run on an AutoDG Droplet Generator
164 (Bio-Rad) with DG32 cartridges according to manufacturer's instructions and analysed using
165 QuantaSoft version 1.7 software (Bio-Rad). All samples were tested in triplicate and droplet data
166 combined for final analysis of heteroplasmy. Heteroplasmy $>2\%$ was considered positive.

167

168 *List of Known pathogenic mitochondrial variants*

169 We reviewed all proposed pathogenic variants from the MitoMAP repository (accessed Oct 2022)
170 <https://mitomap.org/foswiki/bin/view/MITOMAP/ConfirmedMutations>. For this study, we included
171 a variant (n=73, Table S4) if it is curated as pathogenic or likely pathogenic based on the multiple
172 MitoMAP criteria (status = Cfrm)
173 (<https://www.mitomap.org/foswiki/bin/view/MITOMAP/MutationsCodingControlCfrm>) and where available,
174 annotated as pathogenic or likely pathogenic based on the independent criteria defined by the
175 international ClinGen consortium e.g. https://mitomap.org/cgi-bin/search_allele?variant=7445A>G.

176

177 **Statistical analysis**

178 *Mitochondrial genome wide association*

179 We performed single variant association analysis for variants with a MAC ≥ 5 (n=8,896) using
180 REGENIE (v3.1.4) (33) for 15 selected disease/traits (Table S3). REGENIE performs genome wide
181 association testing for large sample sizes and is robust to unbalanced case-control ratios, and
182 controls for population structure by utilising a genetic relatedness matrix generated from common,
183 independent nuclear single nucleotide polymorphisms. To generate the genetic relatedness matrix,
184 we used participants who had both a whole genome sequence and whole exome sequence data
185 available.

186

187 For variants which were only ever heteroplasmic, or only ever homoplasmic in our cohort, we
188 compared them against the reference genotypes. For variants where some individuals were defined
189 as heteroplasmic and some homoplasmic, our primary comparison was individuals with homoplasmic
190 variant versus individuals with heteroplasmic or reference genotype. We performed secondary
191 analysis by comparing heteroplasmic or homoplasmic variant genotypes together versus reference
192 genotypes. We rank inverse normalised the continuous traits and the analysis was adjusted for age
193 at recruitment, sex, sequencing batch, recruitment centre, mitochondrial copy number (mtCN) and
194 the first 40 nuclear genetic principal components (PC). Our significance threshold was the Bonferroni
195 corrected p value of $<3.75 \times 10^{-7}$ calculated by number of variants and traits that were analysed
196 ($=0.05/8896/15$).

197

198 *Rare variant aggregation testing*

199 We performed aggregate testing of rare mtDNA variants (MAF<0.1%) annotated as either missense,
200 synonymous, or loss-of-function by Ensembl VEP (34) which were grouped by mitochondrial
201 transcript, the d-loop, and 100bp sliding windows at 10bp intervals. Previously known pathogenic
202 variants were also grouped by their known disease phenotypes (Table S4). We used REGENIE to
203 perform burden, SKAT and ACAT aggregate tests (33) for association with all 15 traits. We used a
204 Bonferroni corrected p value of $<2 \times 10^{-6}$ as our significance threshold, calculated by number of masks
205 and traits that were analysed ($=0.05/1696/15$).

206

207 *Penetrance of diabetes for m.3243A>G*

208 We used Kaplan-Meier survival estimates to estimate the age-dependent penetrance of diabetes. A
209 log-rank test for equality was used to compare the penetrance of diabetes between the groups.
210 Cox's regression was used to compute the hazard ratio for developing diabetes with or without the
211 adjustment of covariates. The analysis included all individuals without diabetes and individuals with


212 diabetes without missing age at diagnosis (92% of all diabetes cases). We used STATA 16 for all
 213 analysis.

214

215 Results

216 Mitochondrial-wide single variant association identified associations with diabetes, deafness, 217 heart failure and aspartate aminotransferase.

218 We performed single variant association analyses for 8,896 mitochondrial variants (MAC ≥ 5) with 15
 219 disease/traits that are commonly reported in individuals with mitochondrial disease (Tables S3, S5).
 220 In a European-like ancestry analysis, we identified four disorder/traits where variants were
 221 associated at our Bonferroni-corrected significance threshold ($p < 3.75 \times 10^{-7}$) of which enzyme
 222 aspartate aminotransferase (AST) was the only trait with >1 variant association. This included 12
 223 homoplasmic variants associated with AST and only one heteroplasmic variant (m.3243A>G)
 224 associated with diabetes (MAF=0.00024, OR=5.6, 95% CI [3.2-9.9], $P=4 \times 10^{-9}$) and hearing aid use
 225 (OR=12.3, 95% CI [6.2-24.4], $P=6 \times 10^{-13}$ Figure 1A, Table S6). Sensitivity analysis using a higher
 226 heteroplasmy threshold ($\geq 10\%$) observed one additional association of heart failure with the same
 227 m.3243A>G variant (OR=39.5, 95% CI [9.76-160.1]; $P < 3 \times 10^{-7}$; Table S5). Sensitivity analysis using the
 228 dominant model of association (reference vs either heteroplasmic or homoplasmic) did not identify
 229 additional variants and showed consistent results.



230 **Figure 1 – Summary of hypothesis free mitochondrial genome wide associations for 15 mitochondrial**
 231 **disease phenotypes and m.3243A>G associations at increasing heteroplasmy thresholds. A** LocusZoom plot
 232 highlighting all significant associations between mitochondrial variants in the UK Biobank with measured
 233 heteroplasmy $\geq 3\%$ ($n=8,896$, $MAC \geq 5$) and the 15 tested phenotypes. Green dashed line denotes the
 234 Bonferroni-corrected significance threshold ($P < 4.03 \times 10^{-7}$). R^2 Correlation is relative to the most significant
 235 variant in each plot. **B** Forest plot of m.3243A>G associations at increasing minimum heteroplasmy. Solid
 236 points denote associations passing the Bonferroni significance threshold ($P < 3.75 \times 10^{-7}$). Heart failure (all-cause)

237 was the only phenotype to have a significant association in the sensitivity tests for any traits. AST=aspartate
238 transferase.
239

240 **Lead AST associated variant associates with other liver enzymes but not non-alcoholic fatty liver** 241 **disease**

242 Of the 12 primarily homoplasmic variants associated with increased AST levels, three were low
243 frequency novel variants with a large effect size (MAF \sim 0.002, β \sim 0.33) compared to previously
244 known variants (Figure 1, Tables S5, S6, S7). The conditional analysis of each variant for all others
245 showed that the AST associations were led by one previously reported variant: m.15758A>G
246 (MAF=0.02; β =0.09, $P=5 \times 10^{-8}$) (13) and one novel variant: m.13488C>T (MAF=0.002; β =0.33, $P=7 \times 10^{-$
247 11) (Table S6). m.15758A>G causes a missense change in the MY-CYB gene and m.13488C>T is a
248 synonymous change in the MT-ND5, both components of respiratory chain complexes. We next
249 tested the association of these two lead variants with four other liver biomarkers; alanine
250 aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin
251 and, non-alcoholic fatty liver disease (NAFLD). Both these variants associated with increased
252 ALT (beta 0.06 and 0.24 respectively, $p < 6 \times 10^{-4}$) but neither were associated with any other liver
253 markers or non-alcoholic fatty liver disease (Table S8).

254

255 **Rare variant aggregation and other ancestry analyses did not identify additional novel associations**

256 We next performed rare variant (MAF < 0.001) aggregation burden analyses to determine whether
257 rare mtDNA variants were associated with these mitochondrial-related traits. We aggregated rare
258 variants by mitochondrial transcript and for 100bp sliding windows at 10bp intervals. We did not
259 identify any new associations at a Bonferroni-corrected P value ($< 2 \times 10^{-6}$; $= 0.05/1696/15$). We did
260 not identify single or rare variant aggregated associations in an analysis of African-like or South
261 Asian-like ancestry individuals at Bonferroni corrected significance threshold.

262

263 **The m.3243A>G association with diabetes, deafness, and heart failure greatly increases with blood** 264 **heteroplasmy $\geq 10\%$**


265 The variant m.3243A>G was associated with diabetes and deafness at $\geq 3\%$ heteroplasmy and these
266 associations were stronger with higher heteroplasmy. The median m.3243A>G heteroplasmy was
267 7.8% (IQR 5.3-13.1%) for 83 m.3243A>G carriers (all ancestry) in the UKB. Of which, 23% had 3-4.9%,
268 47% had 5-9.9% and 30% had $\geq 10\%$ (Figure S1). Consistent with cross-sectional analysis, we

269 observed higher age-related penetrance of diabetes using Cox proportional hazard model for
270 diabetes (HR 5.8, 95% CI: [3.8-9], $p=3.5 \times 10^{-15}$) in all m.3243A>G carriers compared to non-carriers
271 (Figure S2). Although, the overall risk was higher, this was predominantly driven by individuals with
272 heteroplasmy $\geq 5\%$ (Figure 2A, Table S9). The risk of diabetes was similar to the background/non
273 m.3243A>G carriers for individuals with m.3243A>G heteroplasmy of 3-4.9% (HR 0.98, 95% CI [0.14-
274 6.9], $p>0.9$) but increased to 3.8 (95% CI [1.8-8], $P=3.9 \times 10^{-4}$) for 5-9.9%, and further increased to 20.6
275 (95% CI [11.7-36.4], $P=1.2 \times 10^{-25}$) for individuals with $\geq 10\%$ (Table S9) (P heterogeneity=0.0001). Of
276 the 16,386 individuals with diabetes, m.3243A>G was responsible for 0.14% of diabetes. All results
277 were consistent for unrelated European-like ancestry individuals and when using tertiles of age-
278 adjusted m.3243A>G heteroplasmy (based on a previously published formula (35)) (Figure S3A, Table
279 S10). These data suggest that m.3243A>G level in the blood is an important factor underlying
280 penetrance in a clinically unselected population.

281

282 **m.3243A>G is associated with higher risk of multisystem disorder which increases with higher**
283 **heteroplasmy.**

284 The variant m.3243A>G is commonly associated with a multi-system disorder when ascertained
285 clinically. It is not clear if this occurs when assessed in a hypothesis-free manner in clinically
286 unselected cases, and whether any risk is affected by m.3243A>G levels. To assess this, we grouped
287 mitochondrial-related disorders where we observed the nominal association with m.3243A>G at
288 $p<0.05$ into seven anatomical sites. For example, cardiovascular disorder included non-ischaemic
289 cardiomyopathy all cause heart failure (Table S2). Similar to diabetes, the individuals with 3-4.9%
290 m.3243A>G levels did not have a statistically significant increased risk of having any one disorder or
291 any two disorders (fisher exact test $p>0.1$). However the association became significant with
292 increasing heteroplasmy and, compared to non-carriers, individuals with $\geq 10\%$ m.3243A>G
293 heteroplasmy had a higher chance of having any one disorder (OR 2.75, 95% CI [0.71-9.52], $p=0.076$),
294 increasing to 24.8 (95% CI [8.1-75.7], $p<5.1 \times 10^{-8}$) for any two disorders and 53.50 (95% CI [11.78-
295 199.93], $p<3.5 \times 10^{-6}$) for any three or more disorders (p heterogeneity 0.01) (Figure 2B). Although the
296 risk of multiple features was high compared to non-carriers, it proportionally affected only a small
297 number of total m.3243A>G carriers ($n=83$); 23% ($n=19$) with one disorder, 18% ($n=15$) with two
298 disorders and 7% ($n=6$) with three or more, which increased with higher heteroplasmy (Figure 2C).
299 This indicates that mutation load is an important factor in the expressivity of these multi-system
300 traits in the unselected population.



301 **Figure 2 – Penetrance of diabetes in *m.3243A>G* carriers in clinical and unselected cohorts and associations**
 302 **with multisystem phenotypic presentations. A** Kaplan-Meier survival curves of diabetes for *m.3243A>G*
 303 individuals in the UK Biobank ($n=83$) split by 3-4.9% ($n=19$), 5-9.9% ($n=39$) and $\geq 10\%$ heteroplasmy ($n=25$) and
 304 clinically identified probands with *m.3243A>G* ($n=95$). The log rank test p value for these three groups against
 305 the noncarriers in the UK Biobank were 0.8, 5×10^{-5} , and 9×10^{-71} , respectively. The log rank test p value of UKB
 306 $\geq 10\%$ group against proband was 1×10^{-9} **B** Significant multisystem disorders with one or more presenting
 307 phenotypes of: heart failure (all-cause) or non-ischaeamic cardiomyopathy, constipation, hearing problems,
 308 diabetes, stroke, renal disease, and epilepsy. Hollow points denote non-significant associations when adjusting
 309 for multiple testing ($p < 0.0056$; $p = 0.05/9$) **C** Proportion of *m.3243A>G* carriers ($n=83$) with multiple affected
 310 systems at increasing heteroplasmy thresholds split by 3-4.9% ($N=19$), 5-9.9% ($n=39$) and $\geq 10\%$ heteroplasmy
 311 ($n=25$).

312

313 **Age-related penetrance of diabetes is lower in unselected populations with *m.3243A>G* compared**
 314 **to clinically selected diabetes cohorts**


315 Penetrance estimates based on clinically selected probands are often overinflated for nuclear
 316 monogenic disorders (19). However, this ascertainment effect has not been explored in detail for the
 317 *m.3243A>G* variant. We therefore compared the penetrance of diabetes in the UKB to 95 probands
 318 with diabetes and *m.3243A>G*, identified from routine diabetes clinics (Tables S19-11). The
 319 penetrance of diabetes was 96% (95% CI [90-98]) at age 50 in probands, compared to 15% (95% CI
 320 8.5-26) for carriers in the UKB (log rank test $p = 3 \times 10^{-37}$) (Figure S2). The penetrance remained lower
 321 at 42% (95% CI [23-69]) even when considering individuals with $> 10\%$ heteroplasmy in the UKB

322 compared to proband individuals ($p=1\times 10^{-9}$). The measured m.3243A>G level was higher in probands
323 compared to UKBB (median 7.8 vs 24.6, Figure S1). Therefore, to assess whether the difference in
324 penetrance is explained by difference in m.3243A>G level, we conducted cox proportional hazard
325 model after adjustment for measured m.3243A>G heteroplasmy, age at recruitment, sex, and body
326 mass index (BMI). We found that risk of diabetes in the UKB for individuals with >10% heteroplasmy
327 still remained lower compared to probands (adjusted HR 0.55, 95% CI [0.43-0.7], $p=9\times 10^{-7}$) (Table
328 S11). We observed consistent results using calculated age-adjusted heteroplasmy based on
329 published equation (35) (Table S11). These data suggest that there are additional factors modify the
330 penetrance of diabetes in addition to m.3243A>G levels.

331

332 **Type 2 diabetes genetic risk score (T2DGRS) alters penetrance of diabetes with m.3243A>G.**

333 We hypothesized that nuclear polygenic risk might modify m.3243A>G-related diabetes as seen in
334 nuclear monogenic disorders (36). We found that the risk of any diabetes at 50 years increased from
335 5% (95% CI [1-29]) to 14% (95% CI [4-46]) and 29% (95% CI [14-53]) for m.3243A>G carriers for
336 people with low, medium, and high tertiles of T2DGRS, respectively (Figure 3). This effect was in the
337 same direction after adjusting for m.3243A>G heteroplasmy, age, sex, and mitochondrial copy
338 number (mtCN) with the risk of diabetes in carriers increasing by 1.62-fold (95% CI [0.97-2.7],
339 $p=0.06$) per 1 SD increase in T2DGRS in m.3243A>G carriers. The impact of T2DGRS on diabetes
340 penetrance was similar to that of non-carriers (interaction $p=0.9$). Importantly, this borderline
341 association was maintained with a partitioned T2DGRS representing beta cell dysfunction (HR 1.1,
342 95% CI [1-1.2], $p=0.04$) but not with other non-beta cell partitioned GRS (data not shown). This
343 supports the current understanding that beta cell dysfunction is a primary cause of diabetes in
344 m.3243A>G individuals (37).



345 **Figure 3** – Penetrance of diabetes for individuals with pathogenic *m.3243A>G* variants in an unselected cohort.
346 Kaplan-Meier survival curves of diabetes for *m.3243A>G* carriers split into tertiles (low, mid, and high) of type
347 2 diabetes genetic risk score (T2DGRS) and non-carriers (n=178,340) in the UK Biobank. The log rank test p
348 value for low vs mid and low vs high groups was 0.39 and 0.03, respectively.

349

350 **Most previously reported pathogenic variants are rare in a population cohort.**

351 We next assessed the frequency and association of known pathogenic variants on our 15
352 mitochondrial-related traits. Of 73 well-characterised known pathogenic variants, 13 were not
353 present in UKB (17.81%), 35 were very rare with a frequency of <1:35973 (n≤5 carriers), 17 with a
354 frequency between 1:8994-29977 (n=6-20 carriers), five with a frequency between 1:1799-8565
355 (n=21-100 carriers; *m.1494C>T*, *m.3243A>G*, *m.3460G>A*, *m.8344A>G*, *m.8969G>A*), and three with
356 a frequency >1:1400 (*m.11778G>A*, n=123 carriers; *m.14484T>C*, n=190 carriers; *m.1555A>G*, n=514
357 carriers) (Figure 4, Table S4). Variants causing deafness were most common at 1:263 people (n=684)
358 followed by Leber hereditary optic neuropathy (LHON) disease-causing variants at 1:439 (n=410)
359 although even the more common variants showed very few affected participants, except for
360 *m.3243A>G* (Table 2).

361

362

363

Pathogenic Variant (disease)	Phenotype assessed in UKB	Phenotype frequency in carriers (%)	Phenotype frequency in non-carriers (%)
m.3243A>G (MIDD)	Diabetes	24/83 (28.92)	16362/179867 (0.09)
m.1555A>G (deafness)	Hearing aid use	19/514 (3.7)	6193/179438 (3.45)
m.14484T>C (LHON)	Bilateral visual loss	0/190	124/179762 (0.07)
m.11778G>A (LHON)	Bilateral visual loss	0/123	124/179829 (0.07)
m.1494C>T (Deafness)	Hearing aid use	0/53	6212/179899 (3.45)
m.3460G>A (LHON)	Bilateral visual loss	0/24	124/179928 (0.07)
m.8344A>G (Epilepsy)	Epilepsy	0/22	2635/179929 (1.46)

364 **Table 2: Penetrance of relevant phenotype in carriers of 6 most common pathogenic variants in UKB.**

365 MIDD=Maternally inherited diabetes and deafness. LHON= Leber hereditary optic neuropathy.

366

367 Most of the variants were too rare to perform statistically well-powered single variant analysis.


368 However, for the seven variants (except m.3243A>G) where we had >20 individuals in the EUR-like

369 ancestry cohort, we did not observe association with the mitochondrial-related traits at a

370 Bonferroni-corrected threshold ($p < 0.0006$) (Table S12). We also did not observe association with the

371 respective traits when variants were aggregated by disease-associated phenotypes. The penetrance

372 of relevant traits for these variants were very low and ranged from 0-3.7%.



373

374 **Figure 4 – Minor allele frequency (%) of pathogenic mitochondrial variants in the UKB A The five most**

375 common variants B Variants (n) grouped by disease C The remaining 50 variants present in the UK Biobank.

376 LHON=Leber hereditary optic neuropathy; MIDD=Maternally inherited diabetes and deafness (note:

377 mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) and other phenotypes are
378 also associated with this variant); SLE=Stroke-like episodes.

379

380 Discussion

381 Our study demonstrates that large-scale WGS data offer an exciting opportunity to study the role of
382 mitochondria in human health. This approach can identify important mitochondrial variants and
383 provide novel insights which may lead to the possibility of reporting mitochondrial variants
384 discovered incidentally.

385 Population studies allow a unique opportunity to assess the frequency of pathogenic variants which
386 have been previously identified in cohorts referred because of presenting diseases. The m.3243A>G
387 variant is the most common cause of adult mitochondrial disease and due to its heteroplasmic
388 nature it is absent from whole genome data derived from genotyping arrays. Here we used WGS
389 data to accurately genotype m.3243A>G carriers in a population cohort of ~180,000 participants and
390 identified 83 cases with heteroplasmy $\geq 3\%$ in blood (1 in 2167). This frequency may be an
391 underestimate as it is well known that blood heteroplasmy reduces with age (35) and the mean age
392 of our cohort was 56.89 years (n=179,862; SD=8.1, range 38.83-72.92). Previous attempts at
393 identifying population frequency have been limited to small, and/or selected cohorts, with estimates
394 ranging from 0.017-1.69% (38, 39, 40, 41, 42, 43).

395 We were surprised to find only one variant (m.3243A>G) associated with diabetes despite having
396 large numbers of people with diabetes in our cohort. We observe that penetrance in the unselected
397 population increased with m.3243A>G level, reaching 42% at age 50 for people with measured
398 heteroplasmy of $\geq 10\%$ (age adjusted heteroplasmy ~45%). The risk ratio of diabetes at $\geq 10\%$
399 heteroplasmy (age-adjusted heteroplasmy ~45%) is comparable to that of pathogenic variants in
400 well-known monogenic diabetes genes in the same cohort, as we previously published (19).

401 Although heteroplasmy was a major factor affecting penetrance, we also identify that polygenic risk
402 of type 2 diabetes can also modify the penetrance. These results will need to be replicated in larger
403 cohorts but demonstrate an exciting interplay between nuclear and mitochondrial genome variants
404 responsible for the onset of diabetes in humans. The observation of lower penetrance in an
405 unselected population, compared to a clinically ascertained cohort, has also been recently reported
406 in nuclear monogenic diabetes (19) and in mitochondrial disorders such as LHON (44).

407 Despite the large sample size and examining 15 mitochondrial-related traits the only trait where we
408 have shown multiple mitochondrial variants association is AST. We identified 12 mtDNA variants

409 associated with AST levels, nine of which were previously reported in the same cohort when these
410 variants were called from genotyping array data (13). The novel lead variant m.13488C>T also
411 showed an association with ALT, suggesting that these variants are likely to increase AST level by
412 their effect on the liver, rather than on the heart or skeletal muscle, which can also be sources of
413 AST. The effect size on AST was small, and the lack of association with NAFLD suggests that the high
414 AST level was not due to hepatocellular damage/leakage but may reflect a rise in mitochondrial AST
415 isoform rather than cytoplasmic AST (45, 46). Mitochondrial dysfunction has been reported to play a
416 significant role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD; for review, see (47)).
417 However, we did not identify any genome-wide significant association with NAFLD. Despite a sample
418 size that was substantially larger, we were unable to replicate the previous borderline ($p=0.06$)
419 association of m.16318A>C ($p=0.38$) (48). The original finding may be a false-positive due to the
420 small sample size ($n\sim 300$), but the disparity could also be explained by less well-defined phenotype
421 capture in UKB and a reduced effect size in a non-clinically ascertained cohort.

422 Ours is the largest study of mitochondrial variants based on whole genome sequence data. This
423 provides unique opportunity to assess the population frequency of pathogenic variants which help
424 to better understand the burden of mitochondrial disease in population. We found that most
425 variants were rare in population in line with them causing rare mitochondrial disorders except for
426 some variants causing deafness (m.1555A>G, MAF=0.0014; m.1494C>T, MAF=0.00014) and LHON
427 (m.14484T>C, MAF=0.0005; m.11778G>A, MAF=0.0003). Both m.1555A>G and m.1494C>T cause
428 deafness only after exposure to aminoglycoside antibiotics, which may explain why we failed to
429 detect an association with deafness with either in isolation or when combined (49). We also did not
430 observe an association with bilateral vision loss for the LHON variants ($n=10$) identified. This may be
431 due to a combination of the lower sample size of bilateral vision loss in our cohort ($n=140$) and the
432 well-known low penetrance of the LHON variants in the unselected population (50). Although we
433 used mitochondrial-related traits, our phenotypes were more general and may have overshadowed
434 the specific phenotype of mitochondrial-related diseases (such as stroke-like episodes vs. all strokes
435 (51)). This, along with the low number of pathogenic variants and despite our large cohort, may
436 explain the lack of association of known pathogenic variants in our study.

437 Our study has some limitations. Although our study was one of the largest to assess mitochondrial-
438 wide association, we were still limited in power for non-European-like ancestry populations.
439 Similarly, it is known that the UK Biobank has a healthy volunteer selection bias which is not fully
440 representative of the UK population (52) and may have therefore limited the inferences we can
441 make about multisystem disease. Our stringent sample and variant filter criteria mean that it is
442 possible that we may have excluded true causal or associated variants with these 15 mitochondrial-

443 related traits. However, these stringent criteria allowed us to investigate the association of low level
444 heteroplasmy. This was particularly important for m.3243A>G, which is commonly considered to be
445 present in blood with a heteroplasmy $\geq 3\%$ (35, 53, 54). Some of the phenotypes we assessed had a
446 lower sample size (e.g. bilateral vision loss), which will have limited our ability to robustly assess any
447 associations and would require larger sample sizes to better perform association discovery. We also
448 limited our analysis to single nucleotide variants and small insertions/deletions and did not assess
449 larger deletions, which have been implicated in mitochondrial disease. Additionally, we only used
450 heteroplasmy identified from whole blood samples, which may not reflect heteroplasmy in other
451 tissues or organs that are more relevant to specific mitochondrial diseases.

452 Our study has important implications for the incidental identification of pathogenic mitochondrial
453 variants. Diagnostic molecular genetic laboratories are moving towards using whole-genome
454 sequencing as a first-line genetic test. This, along with a rapid rise in direct-to-consumer testing and
455 use of WGS for research, provides an exciting opportunity to obtain information on pathogenic
456 mitochondrial variants, well before any disease onset. We show that, when detected incidentally
457 from blood, measured m.3243A>G heteroplasmy $\geq 10\%$ (age-adjusted heteroplasmy $\sim 45\%$)
458 significantly increases the risk of diabetes, heart failure, deafness, and that individuals with this level
459 or greater are more likely to experience multiple system disorders. Our findings, combined with the
460 growing availability of prenatal testing for mitochondrial disease, indicate that reporting of
461 m.3243A>G variant when discovered incidentally could have a significant health benefit, particularly
462 for female individuals of reproductive age. If one decides to report this variant when found
463 incidentally, our data suggest that this may be beneficial to individuals with age-adjusted
464 heteroplasmy levels over 45%. However, further studies in unselected population(s) will be needed
465 to refine this advice.

466

467 **Data and Code Availability**

468 The data supporting the findings of this study are available within the article and its Supplementary
469 Data files. Additional information for reproducing the results described in the article is available
470 upon reasonable request and subject to a data use agreement. The UK Biobank dataset is available
471 from <https://biobank.ctsu.ox.ac.uk>.

472

473 **Acknowledgements**

474 This research has been conducted using the UK Biobank Resource. This work was carried out under
475 UK Biobank project number 9072. The current work is funded by Diabetes UK (19/0005994 and
476 21/0006335), MRC (MR/T00200X/1) and Wellcome Trust's Institutional Strategic Support Fund
477 awarded to University of Exeter. KAP is funded by Wellcome Trust (219606/Z/19/Z), ATH is
478 supported by Wellcome Trust Senior Investigator award (WT098395/Z/12/Z) and SJP is funded by
479 the Wellcome Career Re-entry Fellowship (204709/Z/16/Z) and the Wellcome Centre for
480 Mitochondrial Research (203105/Z/16/Z). The work is supported by the National Institute for Health
481 Research (NIHR) Exeter Biomedical Research Centre, Exeter, UK. The Wellcome Trust, MRC and NIHR
482 had no role in the design and conduct of the study; collection, management, analysis, and
483 interpretation of the data; preparation, review, or approval of the manuscript; and decision to
484 submit the manuscript for publication. The views expressed are those of the author(s) and not
485 necessarily those of the Wellcome Trust, Department of Health, NHS or NIHR. For the purpose of
486 open access, the author has applied a CC BY public copyright licence to any Author Accepted
487 Manuscript version arising from this submission.

488

489 **Declaration of Interests**

490 The authors declare no competing interests.

491

492 **References**

- 493 1. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, et al. Mitochondrial
494 diseases. *Nat Rev Dis Primers*. 2016;2:16080.
- 495 2. Thompson K, Collier JJ, Glasgow RIC, Robertson FM, Pyle A, Blakely EL, et al. Recent advances
496 in understanding the molecular genetic basis of mitochondrial disease. *Journal of Inherited
497 Metabolic Disease*. 2020;43(1):36-50.
- 498 3. Li D, Liang C, Zhang T, Marley JL, Zou W, Lian M, et al. Pathogenic mitochondrial DNA
499 3243A>G mutation: From genetics to phenotype. *Front Genet*. 2022;13:951185.
- 500 4. Bernardino Gomes TM, Ng YS, Pickett SJ, Turnbull DM, Vincent AE. Mitochondrial DNA
501 disorders: from pathogenic variants to preventing transmission. *Hum Mol Genet*. 2021;30(R2):R245-
502 r53.
- 503 5. Brandon MC, Lott MT, Nguyen KC, Spolim S, Navathe SB, Baldi P, et al. MITOMAP: a human
504 mitochondrial genome database--2004 update. *Nucleic Acids Res*. 2005;33(Database issue):D611-3.

- 505 6. Reardon W, Ross RJ, Sweeney MG, Luxon LM, Pembrey ME, Harding AE, et al. Diabetes
506 mellitus associated with a pathogenic point mutation in mitochondrial DNA. *Lancet*.
507 1992;340(8832):1376-9.
- 508 7. Kraja AT, Liu C, Fetterman JL, Graff M, Have CT, Gu C, et al. Associations of Mitochondrial
509 and Nuclear Mitochondrial Variants and Genes with Seven Metabolic Traits. *Am J Hum Genet*.
510 2019;104(1):112-38.
- 511 8. Calabrese C, Pyle A, Griffin H, Coxhead J, Hussain R, Braund PS, et al. Heteroplasmic
512 mitochondrial DNA variants in cardiovascular diseases. *PLOS Genetics*. 2022;18(4):e1010068.
- 513 9. Hudson G, Nalls M, Evans JR, Breen DP, Winder-Rhodes S, Morrison KE, et al. Two-stage
514 association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. *Neurology*.
515 2013;80(22):2042-8.
- 516 10. Xia C, Pickett SJ, Liewald DCM, Weiss A, Hudson G, Hill WD. The contributions of
517 mitochondrial and nuclear mitochondrial genetic variation to neuroticism. *Nat Commun*.
518 2023;14(1):3146.
- 519 11. Hudson G, Gomez-Duran A, Wilson IJ, Chinnery PF. Recent mitochondrial DNA mutations
520 increase the risk of developing common late-onset human diseases. *PLoS Genet*.
521 2014;10(5):e1004369.
- 522 12. Ng YS, Lim AZ, Panagiotou G, Turnbull DM, Walker M. Endocrine Manifestations and New
523 Developments in Mitochondrial Disease. *Endocr Rev*. 2022;43(3):583-609.
- 524 13. Yonova-Doing E, Calabrese C, Gomez-Duran A, Schon K, Wei W, Karthikeyan S, et al. An atlas
525 of mitochondrial DNA genotype–phenotype associations in the UK Biobank. *Nature Genetics*.
526 2021;53(7):982-93.
- 527 14. Børte S, Zwart JA, Skogholt AH, Gabrielsen ME, Thomas LF, Fritsche LG, et al. Mitochondrial
528 genome-wide association study of migraine - the HUNT Study. *Cephalalgia*. 2020;40(6):625-34.
- 529 15. Aboulmaouhib B, Kastenmüller G, Suhre K, Zöllner S, Weissensteiner H, Prehn C, et al. First
530 mitochondrial genome-wide association study with metabolomics. *Hum Mol Genet*.
531 2022;31(19):3367-76.
- 532 16. Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Gianotti TF, et al. Mitochondrial genome
533 architecture in non-alcoholic fatty liver disease. *J Pathol*. 2016;240(4):437-49.
- 534 17. Han X, Souzeau E, Ong JS, An J, Siggs OM, Burdon KP, et al. Myocilin Gene Gln368Ter Variant
535 Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies. *JAMA*
536 *Ophthalmol*. 2019;137(1):28-35.

- 537 18. Patel AP, Dron JS, Wang M, Pirruccello JP, Ng K, Natarajan P, et al. Association of Pathogenic
538 DNA Variants Predisposing to Cardiomyopathy With Cardiovascular Disease Outcomes and All-Cause
539 Mortality. *JAMA Cardiol.* 2022;7(7):723-32.
- 540 19. Mirshahi UL, Colclough K, Wright CF, Wood AR, Beaumont RN, Tyrrell J, et al. Reduced
541 penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected
542 cohorts. *Am J Hum Genet.* 2022;109(11):2018-28.
- 543 20. Laricchia KM, Lake NJ, Watts NA, Shand M, Haessly A, Gauthier L, et al. Mitochondrial DNA
544 variation across 56,434 individuals in gnomAD. *Genome Res.* 2022;32(3):569-82.
- 545 21. Halldorsson BV, Eggertsson HP, Moore KHS, Hauswedell H, Eiriksson O, Ulfarsson MO, et al.
546 The sequences of 150,119 genomes in the UK Biobank. *Nature.* 2022;607(7920):732-40.
- 547 22. Venner E, Muzny D, Smith JD, Walker K, Neben CL, Lockwood CM, et al. Whole-genome
548 sequencing as an investigational device for return of hereditary disease risk and pharmacogenomic
549 results as part of the All of Us Research Program. *Genome Medicine.* 2022;14(1):34.
- 550 23. González MDM, Ramos A, Aluja MP, Santos C. Sensitivity of mitochondrial DNA
551 heteroplasmy detection using Next Generation Sequencing. *Mitochondrion.* 2020;50:88-93.
- 552 24. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource
553 with deep phenotyping and genomic data.
- 554 25. Ng YS, Bindoff LA, Gorman GS, Klopstock T, Kornblum C, Mancuso M, et al. Mitochondrial
555 disease in adults: recent advances and future promise. *Lancet Neurol.* 2021;20(7):573-84.
- 556 26. Battle SL, Puiu D, Group TOMW, Verluow J, Broer L, Boerwinkle E, et al. A bioinformatics
557 pipeline for estimating mitochondrial DNA copy number and heteroplasmy levels from whole
558 genome sequencing data. *NAR Genomics and Bioinformatics.* 2022;4(2):lqac034.
- 559 27. Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling Somatic SNVs and
560 Indels with Mutect2. *bioRxiv.* 2019:861054.
- 561 28. Mn W, L J, Jw H, Ks R, J T, At H, et al. Use of SNP chips to detect rare pathogenic variants:
562 retrospective, population based diagnostic evaluation. *BMJ.* 2021;372:n214.
- 563 29. Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. Genome-wide trans-
564 ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes
565 susceptibility. *Nat Genet.* 2014;46(3):234-44.
- 566 30. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, et al. Large-scale
567 association analysis provides insights into the genetic architecture and pathophysiology of type 2
568 diabetes. *Nat Genet.* 2012;44(9):981-90.

- 569 31. Udler MS, Kim J, von Grotthuss M, Bonàs-Guarch S, Cole JB, Chiou J, et al. Type 2 diabetes
570 genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft
571 clustering analysis. *PLoS Med.* 2018;15(9):e1002654.
- 572 32. Singh R, Ellard S, Hattersley A, Harries LW. Rapid and sensitive real-time polymerase chain
573 reaction method for detection and quantification of 3243A>G mitochondrial point mutation. *J Mol*
574 *Diagn.* 2006;8(2):225-30.
- 575 33. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al.
576 Computationally efficient whole-genome regression for quantitative and binary traits. *Nature*
577 *Genetics.* 2021;53(7):1097-103.
- 578 34. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant
579 Effect Predictor. *Genome Biology.* 2016;17(1):122.
- 580 35. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, et al. mtDNA heteroplasmy level
581 and copy number indicate disease burden in m.3243A>G mitochondrial disease. *EMBO Molecular*
582 *Medicine.* 2018;10(6):e8262.
- 583 36. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic
584 scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat*
585 *Genet.* 2018;50(9):1219-24.
- 586 37. Lindroos MM, Majamaa K, Tura A, Mari A, Kalliokoski KK, Taittonen MT, et al. m.3243A>G
587 mutation in mitochondrial DNA leads to decreased insulin sensitivity in skeletal muscle and to
588 progressive beta-cell dysfunction. *Diabetes.* 2009;58(3):543-9.
- 589 38. Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, Kärppä M, et al. Epidemiology
590 of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike
591 episodes: prevalence of the mutation in an adult population. *Am J Hum Genet.* 1998;63(2):447-54.
- 592 39. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochondrial DNA
593 mutations are common in the general population. *Am J Hum Genet.* 2008;83(2):254-60.
- 594 40. Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, Mitchell P, et al. Population
595 prevalence of the MELAS A3243G mutation. *Mitochondrion.* 2007;7(3):230-3.
- 596 41. Odawara M, Sasaki K, Yamashita K. Prevalence and clinical characterization of Japanese
597 diabetes mellitus with an A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA(Leu(UUR))
598 gene. *J Clin Endocrinol Metab.* 1995;80(4):1290-4.
- 599 42. Bouhaha R, Abid Kamoun H, Elgaaied A, Ennafaa H. A3243G mitochondrial DNA mutation in
600 Tunisian diabetic population. *Tunis Med.* 2010;88(9):642-5.
- 601 43. Wang S, Wu S, Zheng T, Yang Z, Ma X, Jia W, et al. Mitochondrial DNA mutations in diabetes
602 mellitus patients in Chinese Han population. *Gene.* 2013;531(2):472-5.

- 603 44. Mackey DA, Ong JS, MacGregor S, Whiteman DC, Craig JE, Lopez Sanchez MIG, et al. Is the
604 disease risk and penetrance in Leber hereditary optic neuropathy actually low? *Am J Hum Genet.*
605 2023;110(1):170-6.
- 606 45. Jiang X, Chang H, Zhou Y. Expression, purification and preliminary crystallographic studies of
607 human glutamate oxaloacetate transaminase 1 (GOT1). *Protein Expr Purif.* 2015;113:102-6.
- 608 46. Glinghammar B, Rafter I, Lindström AK, Hedberg JJ, Andersson HB, Lindblom P, et al.
609 Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues
610 and plasma. *Int J Mol Med.* 2009;23(5):621-31.
- 611 47. Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, et al.
612 Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. *Int J Mol Sci.* 2021;22(9).
- 613 48. Hasturk B, Yilmaz Y, Eren F. Potential clinical variants detected in mitochondrial DNA D-loop
614 hypervariable region I of patients with non-alcoholic steatohepatitis. *Hormones (Athens).*
615 2019;18(4):463-75.
- 616 49. Ealy M, Lynch KA, Meyer NC, Smith RJH. The prevalence of mitochondrial mutations
617 associated with aminoglycoside-induced sensorineural hearing loss in an NICU population. *The*
618 *Laryngoscope.* 2011;121(6):1184-6.
- 619 50. Lopez Sanchez MIG, Kearns LS, Staffieri SE, Clarke L, McGuinness MB, Meteoukki W, et al.
620 Establishing risk of vision loss in Leber hereditary optic neuropathy. *Am J Hum Genet.*
621 2021;108(11):2159-70.
- 622 51. Ng YS, Bindoff LA, Gorman GS, Horvath R, Klopstock T, Mancuso M, et al. Consensus-based
623 statements for the management of mitochondrial stroke-like episodes. *Wellcome Open Res.*
624 2019;4:201.
- 625 52. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
626 Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the
627 General Population. *Am J Epidemiol.* 2017;186(9):1026-34.
- 628 53. Mavraki E, Labrum R, Sergeant K, Alston CL, Woodward C, Smith C, et al. Genetic testing for
629 mitochondrial disease: the United Kingdom best practice guidelines. *Eur J Hum Genet.*
630 2023;31(2):148-63.
- 631 54. de Laat P, Janssen MC, Alston CL, Taylor RW, Rodenburg RJ, Smeitink JA. Three families with
632 'de novo' m.3243A > G mutation. *BBA Clin.* 2016;6:19-24.
- 633